{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T05:25:06Z","timestamp":1778390706030,"version":"3.51.4"},"reference-count":18,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The serum level of leucine-rich \u03b12 glycoprotein (LRG) is a biomarker for active ulcerative colitis (UC). We examined the serum level of LRG as a biomarker for predicting the presence of UC. Patients with persistent diarrhea and\/or bloody stool with no history of UC were consecutively enrolled at their initial visit. Serum LRG measurement and colonoscopy with histology were performed on the same day. We enrolled 103 patients (69 men; median age, 45 years) with suspected UC; 66 patients were diagnosed with active UC (proctitis, n = 10; left-sided colitis, n = 26; and pancolitis, n = 30) based on endoscopic and histological criteria. Although the median LRG value in patients with proctitis was similar to that of patients with normal colonoscopic findings (8.5 vs. 8.6 mg\/mL, p = 0.24), the median LRG values were significantly elevated in patients with left-sided colitis and pancolitis compared with those of patients with normal colonoscopy (13.6 or 18.0 vs. 8.6 mg\/mL, p &lt; 0.0001). The LRG cut-off value of 10.8 \u03bcg\/mL was derived from the ROC curve, showing 96% sensitivity and 97% specificity for active UC but not active proctitis. Using a cut-off value of 10.8 mg\/mL serum, LRG could be a novel biomarker for predicting patients with active UC except for proctitis.<\/jats:p>","DOI":"10.3390\/jcm11216366","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T07:26:50Z","timestamp":1667114810000},"page":"6366","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Serum Leucine-Rich \u03b12 Glycoprotein: A Biomarker for Predicting the Presence of Ulcerative Colitis but Not Ulcerative Proctitis"],"prefix":"10.3390","volume":"11","author":[{"given":"Ichitaro","family":"Horiuchi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Shinshu University Hospital, Matsumoto 390-8621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-1025","authenticated-orcid":false,"given":"Akira","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Digestive Disease Center, Showa Inan General Hospital, Komagane 399-4117, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7985-919X","authenticated-orcid":false,"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Shinshu University Hospital, Matsumoto 390-8621, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Actis, G.C., Pellicano, R., Fagoonee, S., and Ribaldone, D.G. (2019). History of Inflammatory Bowel Diseases. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111970"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1007\/s00535-019-01603-8","article-title":"Estimated prevalence of ulcerative colitis and Crohn\u2019s disease in Japan in 2014: An analysis of a nationwide survey","volume":"54","author":"Murakami","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2009.118919","article-title":"iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases","volume":"69","author":"Serada","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1073\/pnas.82.7.1906","article-title":"Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum","volume":"82","author":"Takahashi","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/ibd.22936","article-title":"Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis","volume":"18","author":"Serada","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis","volume":"11","author":"Shinzaki","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"8825374","DOI":"10.1155\/2021\/8825374","article-title":"Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease","volume":"2021","author":"Yoshimura","year":"2021","journal-title":"Mediat. Inflamm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/gut.47.3.404","article-title":"A reproducible grading scale for histological assessment of inflammation in ulcerative colitis","volume":"47","author":"Geboes","year":"2000","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","article-title":"Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study","volume":"56","author":"Shinzaki","year":"2021","journal-title":"J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1159\/000517339","article-title":"Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study","volume":"102","author":"Yanai","year":"2021","journal-title":"Digestion"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","article-title":"Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease","volume":"11","author":"Yasutomi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e1196","DOI":"10.1016\/j.cgh.2021.06.036","article-title":"Serum Leucine-Rich \u03b12 Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn\u2019s Disease","volume":"20","author":"Kawamoto","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.cgh.2014.06.020","article-title":"Fecal Level of Calprotectin Identifies Histologic Inflammation in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission","volume":"12","author":"Guardiola","year":"2014","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MIB.0000000000000736","article-title":"Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis","volume":"22","author":"Theede","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.3748\/wjg.v24.i38.4384","article-title":"Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis","volume":"24","author":"Urushikubo","year":"2018","journal-title":"World J. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6366\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:04:39Z","timestamp":1760144679000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":18,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11216366"],"URL":"https:\/\/doi.org\/10.3390\/jcm11216366","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]}}}